Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dalzanemdor by Sage Therapeutics for Huntington Disease: Likelihood of Approval
Dalzanemdor is under clinical development by Sage Therapeutics and currently in Phase III for Huntington Disease. According to GlobalData, Phase...
Dalzanemdor by Sage Therapeutics for Mild Cognitive Impairment: Likelihood of Approval
Dalzanemdor is under clinical development by Sage Therapeutics and currently in Phase II for Mild Cognitive Impairment. According to GlobalData,...
Dalzanemdor by Sage Therapeutics for Dementia Associated With Alzheimer's Disease: Likelihood of Approval
Dalzanemdor is under clinical development by Sage Therapeutics and currently in Phase II for Dementia Associated With Alzheimer's Disease. According...
Risk adjusted net present value: What is the current valuation of Sage Therapeutics's Dalzanemdor?
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease. According to...